Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Pozycja w akcjach #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Cena akcji
$64.97
Ostatnia synchronizacja: 2024-05-20
Kapitalizacja rynkowa
$1.97B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategoria

Zyski dla Alpine Immune Sciences, Inc. (ALPN)
Zyski w Mar 2024 TTM: $-36.73M
Według najnowszych raportów finansowych Alpine Immune Sciences, Inc., obecny zysk firmy wynosi $-36.73M. W roku 2022 firma osiągnęła zysk w wysokości $-55.43M, spadek w porównaniu do zysku z roku 2021, który wynosił $-50.42M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Alpine Immune Sciences, Inc. od 2012 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -14,460.11%
US
$1.95B -5,410.35%
NL
$-4.02B 10,833.48%
AU
$-3.09B 8,303.89%
US
- -
CH